Mergers & Acquisitions - Financial

Filter

Current filters:

Financial

Popular Filters

1 to 25 of 110 results

Strides Arcolab makes strategic investment in Oncobiologics

Strides Arcolab makes strategic investment in Oncobiologics

16-07-2014

India’s Strides Arcolab has made a series of strategic investments in Oncobiologics, a privately held…

BiosimilarsBiotechnologyFinancialIndiaMergers & AcquisitionsOncobiologicsStrides Arcolab

Abbott Labs sells branded generics business to Mylan in $5.3 billion deal

Abbott Labs sells branded generics business to Mylan in $5.3 billion deal

14-07-2014

Following a weekend of rumors and speculation, USA-based generics major Mylan and health care firm Abbott…

Abbott LaboratoriesAustraliaCanadaEuropeFinancialGenericsJapanMergers & AcquisitionsMylanNew Zealand

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Pharma more optimistic about future despite upcoming industry consolidation

Pharma more optimistic about future despite upcoming industry consolidation

13-06-2014

More than 69% of senior players within the pan-world pharma industry expect to see a year-on-year increase…

FinancialGlobalMergers & AcquisitionsPharmaceutical

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

AMRI to acquire Cedarburg Pharmaceuticals in $41 million deal

24-03-2014

Albany Molecular Research, a USA-based contract research and manufacturing organization, has signed a…

Albany Molecular ResearchCedarburg PharmaFinancialGenericsMergers & Acquisitions

Vectura to buy Germany’s Activaero for 130 million euros

Vectura to buy Germany’s Activaero for 130 million euros

14-03-2014

UK developer of inhaled therapies Vectura says it is acquiring privately-held German company Activaero…

ActivaeroFinancialMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Increasing investment in Latin American pharma market

Increasing investment in Latin American pharma market

12-02-2014

Around $12.7 billion has been invested in Latin America’s pharmaceutical market through mergers and…

ArgentinaBrazilChileEcuadorFinancialMergers & AcquisitionsPharmaceuticalSouth America

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

22-01-2014

German pharma and life sciences group Bayer says it is taking advantage of currently low interest rates…

AlgetaBayerFinancialMergers & AcquisitionsPharmaceutical

NeXeption forms new company, Alexar Therapeutics, to develop novel LXR agonist portfolio

03-01-2014

US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to…

A-110Alexar TherapeuticsDermatologicalsFinancialMergers & AcquisitionsNeXeptionPharmaceuticalResearch

OPKO takes 10-fold profit on sale of stake in Sorrento Therapeutics

20-12-2013

US drugmaker OPKO Health says it has completed the sale of its stake in Sorrento Therapeutics, a clinical-stage…

FinancialMergers & AcquisitionsOPKO HealthPharmaceuticalSorrento Therapeutics

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

16-12-2013

A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Adcock Ingram pleads case for CFR bid; delivers strong revenue growth

Adcock Ingram pleads case for CFR bid; delivers strong revenue growth

28-11-2013

South African drugmaker Adcock Ingram yesterday made the case for accepting a takeover from Chile largest…

Adcock IngramCFR PharmaceuticalsFinancialMergers & AcquisitionsPharmaceuticalRest of the World

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

GlaxoSmithKline cashes in $694 million of Aspen shares

GlaxoSmithKline cashes in $694 million of Aspen shares

21-11-2013

UK pharma giant GlaxoSmithKline said yesterday that it has agreed to the sale of 28.2 million ordinary…

Aspen PharmacareFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

19-11-2013

Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

1 to 25 of 110 results

Back to top